CLAIMS

1. A compound of Formula A:


(A)

or a pharmaceutically acceptable salt thereof, wherein:

Ar^1 is phenyl substituted with halogen, CN, OH, C_{1-3} alkyl optionally substituted with one or more halogens, or C_{1-3} alkoxy;

R^2 is H or C_{1-3} alkyl;

Ar^2 is pyridine, optionally substituted with halogen, OH, amine, or C_{1-3} alkyl;

R^4 is hydrogen or C_{1-4} alkyl; and

wherein Formula (A) excludes the following compounds:

,
,
,
,
,
, and
.

2. The compound of claim 1, wherein Ar^1 is a phenyl substituted by at least one R^1 that is CN or halogen.

3. The compound of claim 2, wherein Ar^1 is substituted by one or two R^1 groups independently selected from C_{1-3} alkyl optionally substituted with one or more halogens, halogen, CN or OH.

4. The compound of any one of claims 1-3, wherein R^2 is H or CH_3.

5. The compound of any one of claims 1-4, wherein R^4 is H.

6. The compound of any one of claims 1-4, wherein R^4 is C_{1-4} alkyl.

7. The compound of claim 1, having a structure according to Formula (II):



(II)

or a pharmaceutically acceptable salt thereof, wherein:

m is 1, 2, 3, or 4;

n is 0, 1, or 2;

R^1, each time taken, is independently selected from the group consisting of hydrogen, halogen, CN, OH, C_{1-3} alkyl optionally substituted with one or more halogens, and C_{1-3} alkoxy;

R^2 is hydrogen or C_{1-3} alkyl;

R^3, each time taken, is independently selected from the group consisting of halogen, OH, amine, or C_{1-3} alkyl; and

R^4 is hydrogen or C_{1-4} alkyl.

8. The compound of claim 7, having the structure of Formula (IIa):



(IIa)

or a pharmaceutically acceptable salt thereof

9. The compound of claim 7, having the structure of Formula (IIb):



(IIb)

or a pharmaceutically acceptable salt thereof.

10. The compound of claim 7, having the structure of Formula (IIc):



(IIc)

or a pharmaceutically acceptable salt thereof.

11. The compound of claim 7, having the structure of Formula (IId):



(IId)

or a pharmaceutically acceptable salt thereof.

12. The compound of claim 7, having the structure of Formula (IIe):



(IIe)

or a pharmaceutically acceptable salt thereof.

13. The compound of claim 7, having the structure of Formula (IIf):



(IIf)

or a pharmaceutically acceptable salt thereof.

14. The compound of claim 7, having the structure of Formula (IIg):



(IIg)

or a pharmaceutically acceptable salt thereof.

15. The compound of claim 1, having a structure according to Formula III:



(III)

or a pharmaceutically acceptable salt thereof, wherein:

m is 1, 2, 3, or 4;

n is 0, 1, or 2;

R^1, each time taken, is independently selected from the group consisting of hydrogen, halogen, OH, and C_{1-3} alkyl optionally substituted with one or more halogens;

R^2 is hydrogen or C_{1-3} alkyl;

R^3, each time taken, is independently selected from the group consisting of halogen, OH, amine, and C_{1-3} alkyl;

R^4 is hydrogen or C_{1-4} alkyl;

R^5 is CN or halogen.

16. The compound of claim 15, having the structure of Formula (IIIa):



(IIIa)

or a pharmaceutically acceptable salt thereof.

17. The compound of claim 15, having the structure of Formula (IIIb):



(IIIb)

or a pharmaceutically acceptable salt thereof.

18. The compound of claim 15, having the structure of Formula (IIIc):



(IIIc)

or a pharmaceutically acceptable salt thereof.

19. The compound of claim 15, having the structure of Formula (IIId)



(IIId)

or a pharmaceutically acceptable salt thereof.

20. The compound of claim 15, having the structure of Formula (IIIe):



(IIIe)

or a pharmaceutically acceptable salt thereof.

21. The compound of claim 15, having the structure of Formula (IIIf):



(IIIf)

or a pharmaceutically acceptable salt thereof.

22. The compound of claim 15, having the structure of Formula III(g):



III(g)

or a pharmaceutically acceptable salt thereof.

23. The compound of any one of claims 7-22, wherein m is 1.

24. The compound of any one of claims 7-22, wherein m is 2.

25. The compound of any one of claims 7-22, wherein m is 3.

26. The compound of any one of claims 7-14, wherein m is 4.

27. The compound of any one of claims 7-8, 11, 14-16, 19 and 22, wherein n is 0.

28. The compound of any one of claims 7-8, 11, 14-16, 19 and 22, wherein n is 1.

29. The compound of any one of claims 7-8, 11, 14-16, 19 and 22, wherein n is 2.

30. The compound of any one of claims 7-22, wherein R^1 is hydrogen.

31. The compound of any one of claims 7-22, wherein R^1 is halogen.

32. The compound of claim 31, wherein R^1 is F.

33. The compound of claim 31, wherein R^1 is Cl.

34. The compound of claim 31, wherein R^1 is Br.

35. The compound of any one of claims 7-22, wherein R^1 is CN.

36. The compound of any one of claims 7-22, wherein R^1 is OH.

37. The compound of any one of claims 7-22, wherein R^1 is C_{1-3} alkyl optionally substituted with one or more halogens.

38. The compound of claim 37, wherein R^1 is C_{1-3} alkyl.

39. The compound of claim 37, wherein R^1 is methyl.

40. The compound of claim 37 wherein R^1 is ethyl.

41. The compound of claim 37, wherein R^1 is CF_3.

42. The compound of any one of claims 7-22, wherein R^1 is C_{1-3} alkoxy.

43. The compound of claim 42, wherein R^1 is methoxy.

44. The compound of any one of claims 7-10 and 15-18, wherein R^2 is hydrogen.

45. The compound of any one of claims 7-10 and 15-18, wherein R^2 is C_{1-3} alkyl.

46. The compound of claim 45, wherein R^2 is methyl.

47. The compound of any one of claims 7-8, 11, 14-16, 19 and 22, wherein R^3 is halogen.

48. The compound of claim 37, wherein R^3 is F.

49. The compound of any one of claims 7-8, 11, 14-16, 19 and 22, wherein R^3 is OH.

50. The compound of any one of claims 7-8, 11, 14-16, 19 and 22, wherein R^3 is amine.

51. The compound of claim 50, wherein R^3 is NH_2.

52. The compound of any one of claims 7-8, 11, 14-16, 19 and 22, wherein R^3 is C_{1-3} alkyl.

53. The compound of claim 52, wherein R^3 is methyl.

54. The compound of any one of claims 7, 9, 12, 14, 17, 20, and 22, wherein R^4 is hydrogen.

55. The compound of any one of claims 7, 9, 12, 14, 17, and 22, wherein R^4 is C_{1-4} alkyl.

56. The compound of claim 55, wherein R^4 is methyl.

57. The compound of claim 55, wherein R^4 is ethyl.

58. The compound of claim 55, wherein R^4 is isopropyl.

59. The compound of claim 55, wherein R^4 is *tert*-butyl.

60. The compound of any one of claims 15-22, wherein R^5 is F.

61. The compound of any one of claims 15-22, wherein R^5 is Cl.

62. The compound of any one of claims 15-22, wherein R^5 is Br.

63. The compound of any one of claims 15-22, wherein R^5 is CN.

64. The compound of claim 1, which is selected from the group consisting of:

Compd. No.	Structure	Cmpd. No.	Structure
1		2	
3		4	
5		6	
7		8	
9		10	
11		12	
13		14	

15		16	
		18	
19		20	
21		22	
23		24	
25		26	
27		28	

29		30	
31		32	
33		34	
		36	
37		38	
39		40	
		42	
		44	

or a pharmaceutically acceptable salt thereof

65. The compound of any one of claims 1-64, or a pharmaceutically acceptable salt thereof wherein at least one hydrogen atom is replaced with a deuterium atom.

66. A pharmaceutical composition comprising the compound of any one of claims 1-65, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

67. Use of a compound of any one of claims 1-65 in the manufacture of a medicament for treating a disease mediated by PHD activity in a subject, wherein the disease mediated by PHD activity is selected from an ischemic reperfusion injury, inflammatory bowel disease, cancer, liver disease, artherosclerosis, cardiovascular disease, a disease or condition of the eye, anemia, chronic kidney disease, acute lung injury, pulmonary fibrosis, pulmonary hypertension, chronic obstructive pulmonary disease, and a disease associated with hyperoxia.

68. The use of claim 67, wherein the disease mediated by PHD activity is an ischemic reperfusion injury.

69. The use of claim 68, wherein the ischemic reperfusion injury is selected from stroke, myocardial infarction, and acute kidney injury.

70. The use of claim 67, wherein the disease mediated by PHD activity is inflammatory bowel disease.

71. The use of claim 70, wherein the inflammatory bowel disease is ulcerative colitis.

72. The use of claim 70, wherein the inflammatory bowel disease is Crohn's disease.

73. The use of claim 67, wherein the disease mediated by PHD activity is cancer.

74. The use of claim 73, wherein the cancer is colorectal cancer.

75. The use of claim 67, wherein the disease mediated by PHD activity is liver disease.

76. The use of claim 67, wherein the disease mediated by PHD activity is atherosclerosis.

77. The use of claim 67, wherein the disease mediated by PHD activity is cardiovascular disease.

78. The use of claim 67, wherein the disease mediated by PHD activity is a disease or condition of the eye.

79. The use of claim 78, wherein the disease or condition of the eye is selected from radiation retinopathy, retinopathy of prematurity, diabetic retinopathy, age-related macular degeneration, and ocular ischemia.

80. The use of claim 67, wherein the disease is anemia.

81. The use of claim 80, wherein the anemia is anemia associated with chronic kidney disease.

82. The use of claim 67, wherein the disease is chronic kidney disease.

83. The use of claim 67, wherein the disease is associated with hyperoxia.

84. The use of claim 83, wherein the disease is retinopathy of prematurity.

85. The use of claim 83, wherein the disease is bronchopulmonary dysplasia (BPD).

86. The use of claim 67, wherein the disease is selected from ischemic heart disease, valvular heart disease, congestive heart failure, acute lung injury, pulmonary fibrosis, pulmonary hypertension, chronic obstructive pulmonary disease (COPD), acute liver failure, liver fibrosis, and cirrhosis.